Defining and Addressing Preclinical Alzheimer’s Disease
What if there was a way to detect Alzheimer’s disease before clinical signs and symptoms even appeared? Dr. Reisa Sperling joins Dementia Matters for a two-part series covering her research on detecting and treating Alzheimer’s disease at the earliest possible stage, known as preclinical Alzheimer’s. In this episode, Dr. Sperling goes in-depth on amyloid and tau proteins and the implications on early detection and treatment strategies for Alzheimer’s disease. Guest: Reisa Sperling, MD, director, Center for Alzheimer Research and Treatment (CART), co-principal investigator, Harvard Aging Brain Study, principal investigator, Alzheimer’s Clinical Trials Consortium (ACTC), co-leader, A4 Study, co-leader, AHEAD 3-45 Study, professor of neurology, Harvard Medical School Show Notes Read more about the Harvard Aging Brains Study on their website. Read more about the AHEAD Study on their website. Watch “ Voices from the AHEAD Alzheimer’s Disease Trial ,” featuring Dr. Cynthia Carlsson and a research participant, on YouTube. Learn more about the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s disease (A4) study here. Learn more about Dr. Sperling in her profile on the Massachusetts General Hospital website . Connect with us Find transcripts and more at our website . Email Dementia Matters : dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter . Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter . Enjoy Dementia Matters ? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s . All donations go toward outreach and production.